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Changes of coagulation factors in patients with
carcinomas and carcinomas of the breast; perioperative
influence of local anesthetics
After Croatian Register for Cancer there are approximately 2300new cases diagnosed each year in Croatia. Breast cancer is the most
common cause of death in women and accounting for more than 800
deaths a year. In 2010. in University Hospital for Tumors 600 patients
had breast biopsy for suspicious breast tumors and afterward therapy
after protocol for breast cancer. Patients with carcinoma are at risk of
coagulopathy which can be first sign of malignant disease. Trombela-
stometry (TEG) is fast diagnostic method for differentiation hyper-
coagulation and hyperfibrinolytic conditions and their causes. TEG
allow the dynamic assesment of haemostatic profile and in that way can
be early predictor of breast carcinoma,differentiation between benign
and malignant breast tumors and provide early therapy for carcinoma.
Breast cancers are the second most common cancer in women
immediately after skin cancer. In the U.S. the 2010th estimated number
of new cases of breast cancer was 207 090 (women) and 1970 (men) to
the annual fatal: 39 840 (women) and 390 (men) (www.cancer.gov). In
the last 20 years there has been a significant increase in the incidence
mainly due to increased detection with screening mammography. Pa-
tients with breast cancer have been treated by resection of breast tissue
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DVD – deep venous thrombosis
FXII – Factor 12
FVIII – von Willebrand factor
u-PA – urokinase plasminogen activator
PAI-1 – plasminogen activator inhibitor 1
t-PA – tissue plasminogen activator
VTE – thromboembolism
TAT – thrombin-antithrombin complexes
AT – antithrombin
ALL – acute lymphoblastic leukemia
PC – protein C
PC – protein S
NKT – natural killer T cells.
IL-1 – interleukin-1
VEGF – Vascular endothelial growth factor
VPF – vascular permeability factor
TNF- – tumor necrosis factor-alpha
LA – local anesthetics
Cancer patients are at increased risk of developing
venous thromboembolism(VTE). Studies have shown
that the risk is up to 6 times greater in patients with
cancer. Tumor cell alters both host immunocompetent
cells and activation of coagulation through a series of ac-
tivations and secretions. Tumor itself gives rise to trans-
formation of the host immunocompetent cells. Macro-
phages transform to so-called M2 cells characterized by
lower antigen presenting ability. These alterations result
in suppression of T cell response and immunosuppres-
sion. M2 cells enhance angiogenesis and tumor tissue
proliferation. Vascular endothelial growth factor (VEGF)
and inflammatory cytokines (TNF-a and IL-1b) from
tumor cell stimulate tissue factor secretion by the macro-
phages and endothelium, as well as platelet adhesion to
vascular endothelium and cell tumor-endothelium inter-
action resulting in FXII activation. The fibrinolytic sys-
tem balance is severely impaired by the increased syn-
thesis of urokinase plasminogen activator (u-PA) and
plasminogen activator inhibitor 1 (PAI-1), and a decreas-
ed synthesis of tissue plasminogen activator (t-PA) (8).
Thrombelastography (TEG) is a fast diagnostic meth-
od for differentiation hypercoagulable and hyperfibrino-
lyric states and its causes. TEG takes into account inter-
reaction between fibrinogen, platelet and protein coagu-
lation cascade. Using whole blood give us information
about cumulative effect of various parameters of plasma
factors, platelets, white blood cells at all stages of the
coagulation process and fibrinolysis. In addition to the
quantitative data we get also graphic presentation of clot
formation and its decomposition. TEG is a dynamic
evaluation of hemostatic profile in contrast to the static
conventional coagulation parameters (9).
In patients with malignant disease frequent clotting
disorders may be the first manifestation of their malig-
nancy. These disorders can be the result of pathophysio-
logical events in the growth of malignant tumors and the
consequences of their treatment. Venous thrombo-embo-
lism (VTE) is a common complication in patients under-
going surgery. Cance rsurgery seems to have at least twice
the risk of postoperative deep vein thrombosis (DVT)
and more than 3 times the risk of fatal pulmonary embo-
lism (PE) than similar procedures in non cancer patients
(10). In the study of Robert H. I. Andtbacka et alt., 3898
patients with breast cancer underwent 4416 surgical pro-
cedures. Seven patients with postoperative VTE within
60 days were identified, for a rate of 0.16% per procedure
(11). In Paulo Prandoni et al. study of the 842 included-
patients, 181 had known cancer at entry. The 12-month
cumulative incidence of recurrent thromboembolism in
cancer patients was 20.7% (95% CI, 15.6%–25.8%) versus
6.8% (95% CI, 3.9%–9.7%) in patients without cancer,
for a hazard ratio of 3.2 (95% CI, 1.9–5.4) (12).
During the growth tumors produce proteolytic enzy-
mes that degrade the surrounding tissue and thus allow
propagation of the malignant process. The most impor-
tant is the matrix metalloproteinases (collagenase type 4),
which allows the destruction of the basement membrane,
which is necessary for the process neoangiogenesis, for-
mation of new blood vessels of the tumor. Tumor blood
vessels are anatomically imperfect, have numerous de-
fects in the endothelium, what at the same time leads to
bleeding and clotting activation process, and will there-
fore in most patients with malignant diseases be present
in the laboratory findings as activated clotting process.
Clinically visible clotting disorders do not perceive it in
all patients with laboratory markers of activated clotting
process. Their frequency have been increased during in-
vasive diagnostic and therapeutic procedures, radiothe-
rapy, surgery, use of central venous catheters or during the
administration of chemotherapy. The occurrence of throm-
boembolism (TE) in patients with cancer is one of the
indicators of their poorer outcomes (12).
Tumor cells during growth release proteases, collage-
nase type 4, known as matrix metalloproteinases, which
is released on intraluminal surface of endothelial cells
and have been involved in direct fibrinolytic activity,
which leads to destruction of the basement membrane of
blood vessels, a process that is essential for the formation
of new capillaries and tumor growth. Tumor cells release
stimulatory factors, such as growth factors (vascular en-
dothelial growth factor, VEGF) and core permeability
factor (vascular permeability factor, VPF). VEGF stimu-
lates the proliferation of endothelial cells in the extracel-
lular space. VEGF / VPF increase microvascular perme-
ability, induces migration of endothelial cells, enhance
their proliferation and survival. While covering the endo-
thelium of blood vessels in the area there are many gaps,
and the relationship between endothelial cells and peri-
cytes are much looser, endothelial cells are not tight to the
basement membrane and in some places are accumulated
in multiple layers (13). These blood vessels have increas-
ed permeability, and through them have been increased
release of plasma proteins, including prothrombin and
fibrinogen in the extracellular matrix. Prothrombin is
converted into thrombin and leads to activation of the
clotting process, the conversion of fibrinogen to fibrin
with formation of fibrin degradation products (FDP).
Activation of platelets within the anatomical imper-
fect vessels will lead to the expression of GPIIb / IIIa (or
a11bb3, from the group of integrins), the complex of two
platelet glycoprotein involved in platelet adhesion to the
vessel wall (14). After activation platelets release growth
factors and produce aggregates within which are linked
fibrin network. Because of this process in patients with
tumor disease there is an increased consumption and
reduced life span of platelets. In the early stages of tumor
disease platelet count can therefore be increased. Kuenen
(15) has noted increased platelet counts in 40% of pa-
tients with malignant diseases. In advanced stages of ma-
lignant diseases commonly have been observed decreased
platelet count, which is associated with poor prognosis.
Decrease in the number of platelets occurs as a result of
consumption of platelets due to bleeding in the tumor
and surrounding tissue.
Anomalies in tumor microvasculature promote activa-
tion of clotting process externally in circulation to relieve
clotting factors, the concentration of which is proportional
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to the stage of the tumor, the intensity of angiogenesis
and metastasis. Therefore, in malignant disease usually
have been found increased concentration of clotting fac-
tors, particularly tissue factor (TF), a proteolytic enzyme
synthesized by different bodies. Elevated levels of soluble
tissue factor in the circulation have been increased with
increased thrombogenic potential of tumors. Activation
of the extrinsic pathway of coagulation in tumors leads to
the activation cascade of proteolytic enzymes and the
conversion of prothrombin to thrombin, which is the
strongest procoagulable enzyme in the body. Its perfor-
mance leads to the degradation of fibrinogen in fibrin
monomers and creating extracellular fibrin network. In
this process the resulting degradation are products: pro-
thrombin fragments 1 and 2, fibrin degradation products
of D-dimers. Immunohistochemical staining of these
degradation products have been proven in extacellular
matrix, and their concentration is higher in large tumors,
malignant tumors with deep infiltrate of surrounding tis-
sues and metastases in the lymph nodes. Studies have shown
a significant correlation of these degradation products and
tissue factor (16).
FVIII / von Willebrand factor are two different glyco-
proteins that circulate in the plasma as a complex of FVIII
/ VWF. VWF is synthesized by endothelial cells and me-
gakaryocytes, and it helps the adhesion of platelets to
activated endothelium and maintain links between plate-
lets during thrombus formation. VWF plays a significant
role in the creation, operation and stabilization of FVIII,
serves as his carrier and as a cofactor for FVIII in plasma.
Factor VIII acts as a cofactor that accelerates the activation
of FX by activated FIX in the clotting process. Increased
synthesis of VWF, which correlated with tumor grade
observed in the majority of cancers, including breast can-
cer (17).
Counterbalance procoagulable processes in malignant
diseases are natural anticoagulants: protein C, protein S
and antithrombin. Antithrombin is the most important
natural inhibitor of thrombin. He inactivate the irreversi-
able reaction that generates thrombin-antithrombin com-
plexes (TAT). Higher TAT values that reflect the acti-
vation of the clotting process and increased consumption
of AT were observed in acute lymphoblastic leukemia
(ALL) (18). Because consumer activation clotting process,
the value of AT, protein C and protein S in the circulation
are usually reduced. To hypercoagulability also contri-
butes acquired and acquired resistance to the effect of
protein C (APC-resistence), a disorder that is often ob-
served in malignant disease, and disappears after the re-
moval or cure of malignant diseases (19).
In patients with breast cancer will be changes in trom-
belastogram (abbreviated coagulation time and forma-
tion of a clot with increased á angle and maximum clot
firmness) and coagulation factors system (increased pla-
telets, increased platelet aggregation, prolonged PT and
APTT, fibrinogen, D-dimer, VWF, PAI-1, and decreased
AT, PS, PC and plasminogen) in terms of diathesis,
while we do not expect such changes in benign changes
SURGERY AND REGIONAL ANESTHESIA
Coagulation disorders may have a significant impact
on the clinical perioperative outcomes in cancer popu-
lation as a consequence of tumor growth, chemotherapy,
radiotherapy or due to the surgical trauma. Surgery pro-
motes the formation of fibrin and platelet clots around
tumor cell emboli, thereby impairing natural killer cell-
-mediated tumor cell clearance, whereas perioperative
anticoagulation attenuates this effect (20). Undergoing
surgical procedure presents an additional stress for the or-
ganism. Coagulation and anticoagulation inhibitor values
analysis of perioperative measurements should have ans-
wered questions about a pathophysiological processes
that are activated during the operation, but which are
also blocked by applied Low molecular weight hepa-
rines, which has an antithrombin, profibrinolytic and
antiaggregational effect (21). Changes in coagulation and
fibrinolysis inhibitor activity can perioperatively cause
trombosis and/or bleeding (22). Awareness of underlying
mechanisms should point to preventive strategies, early
diagnostics, and appropriate treatment of cancer and
coagulation disorders associated. By activating t-PA and
blocking PAI-1, thromboprophylaxis with LMW Hepa-
rin creates a stable and balanced perioperative system of
haemostasis. Those may have a significant impact on the
clinical outcomes in this suspectible population.
It is known that hematogenous dissemination of can-
cer cells occurs during the surgical resection of a tumor
(23). Recent studies confirmed that the circulating tumor
cells were detected in the blood 24 h postoperatively, and
there are an independent prognostic marker for cancer
recurrence because of the ability of these cells to extra-
vasate and metastasize (24). Also, It has been shown that
opioids even at clinically useful concentrations might
promote migration and proliferation of tumor cells, e.g.,
in breast cancer (25, 26). Authors with the results of
study, suggest that the perioperative administration of
local anesthetics(LA) may have the potential added be-
nefit of attenuating extravasation and metastasis of circu-
lating tumor cells (27). The potential beneficial effect of
regional anesthesia to improve long-term outcome after
cancer surgery has been attributed to inhibition of the
surgical stress response and to the decrease in opioid
requirements. At the recent knowledge exert a possible
mechanism by which local anesthetics might be bene-
ficial in patients with cancer and/or undergoing cancer
surgery and that this mechanism may be because of, at
least in part, inhibition of Src tyrosine kinase, a key
enzyme in cancer growth and metastasis (27).
The benefit of paravertebral block with local anaesthe-
tics to be proven in major breast procedures, and the pain
relief was superior compared to general anesthesia. It is
left to investigate place of regional anestehsia in minor
breast surgical procedures (28).
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